By disrupting these pathways, PRPK inhibition not only halts tumor progression but also fosters an immunologically active TME, showcasing its potential as a preventive or therapeutic target for UV-induced skin cancers and beyond. The gene discussed is TP53RK; the disease is skin neoplasm.